Download guidelines and get practical tips for successful formulation of sustained release tablets with Compritol® 888 ATO
Compritol® 888 ATO combines several advantages when used as a sustained release matrix agent:
- Drug release from a Compritol® 888 ATO matrix is diffusion controlled and not driven by swelling and erosion. This facilitates simple product design, including straightforward modulation of drug release and high reproducibility.
- A Compritol® 888 ATO matrix is not sensitive to physiological variations such as pH, digestion or alcohol. It makes biopharmaceutically robust tablets.
- Versatile use of Compritol® 888 ATO in many processing techniques favors product optimization and provides scope for innovation in solid oral dosage form development.
To help formulation scientists develop formulations with Compritol® 888 ATO, Gattefossé has edited formulation guidelines. It aims to provide comprehensive and clear information on the physico-chemical and biopharmaceutical properties of Compritol® 888 ATO and how this highly versatile excipient can be used to create effective sustained release (SR) matrices. A detailed description of Compritol® 888 ATO characteristics and specifications is provided as well as tips for tablet formulation and manufacturing processes. Case studies illustrate the potential of Compritol® 888 ATO in SR formulation. Practical solutions to common problems encountered in SR development are also included.
You can freely download this formulation guidelines at Gattefossé until February 28th, 2020.